Minimizing Delirium With Nasal Dexmedetomidine-Induced Sleep in Older Patients Undergoing Major Abdominal Surgery: : a Randomized, Double-blind, Placebo-controlled Trial
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Enrollment
- 400
- Primary Endpoint
- Incidence of postoperative delirium
Overview
Brief Summary
This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.
Detailed Description
Delirium is an acute, short-term brain dysfunction characterized by fluctuating consciousness, cognitive decline, inattention, and sleep-wake cycle disruption. Postoperative delirium (POD), occurring predominantly within the first postoperative week (especially days 3-5 in elderly patients), affects 11-45% of older adults after major surgery. POD prolongs hospitalization, increases morbidity and mortality 5,65,6, yet its pathophysiology remains unclear, and evidence-based pharmacological prevention is lacking. Thus, effective POD prevention strategies are urgently needed.
Preoperative anxiety, a modifiable risk factor for POD, affects 11-80% of surgical patients. It contributes to sleep disturbances (e.g., insomnia, early awakening), which may exacerbate POD via neuroendocrine and immune dysregulation. However, benzodiazepines (e.g., lorazepam, diazepam, midazolam), though effective anxiolytics, increase delirium risk and are contraindicated preoperatively per current guidelines.
Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, induces physiological non-REM sleep without respiratory depression or hemodynamic instability. Its nasal formulation offers high bioavailability (82%), ease of administration, and is approved in China for preoperative sedation/anxiety. While intravenous (IV) DEX reduces POD in predominant ICU settings, its use in general wards remains unexplored. Preclinical studies suggest DEX enhances glymphatic clearance and exerts anti-inflammatory effects, potentially mitigating the development of POD. This study thus hypothesize that a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patient population. We set to demonstrate that to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in older patients undergoing major abdominal surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 65 Years to 90 Years (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged 65-90 years
- •Scheduled for a major abdominal surgery with estimated surgery time ≥ 2 hours
Exclusion Criteria
- •Blind, deafness or the inability to speak mandarin
- •Allergy to dexmedetomidine.
- •Renal and liver failure requiring dialysis or Child-Pugh score \> 5
- •Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)
- •Previous major abdominal or cardiac surgery within 1 year of surgical procedure
- •Chronic therapy with benzodiazepines and/or antipsychotics. Severe deficit due to structural or anoxic brain damage
- •Body weight \< 35 kg
Arms & Interventions
Placebo
Intervention: Placebo (Drug)
Dexmedetomidine
Intervention: Dexmedetomidine (Drug)
Outcomes
Primary Outcomes
Incidence of postoperative delirium
Time Frame: Up to postoperative day (POD) 7 or discharge (whichever first).
Confusion Assessment Method
Secondary Outcomes
- Delirium severity(Up to postoperative day (POD) 7 or discharge (whichever first))
- Physical activity(Up to postoperative day (POD) 3)
- Sleep quality(Up to postoperative day (POD) 3)
- Anxiety(Up to postoperative day (POD) 3)
- Pain intensity(Up to postoperative day (POD) 3)
- Opioid consumption(Up to postoperative day (POD) 3)
- Health related quality of life(On postoperative day (POD) 3 and 30)
- Quality of Recovery(Up to postoperative day (POD) 3)
- Postoperative Nausea and Vomiting(Up to postoperative day (POD) 3)
- Post-anesthesia Care Unit (PACU) length of stay(Up to postoperative day (POD) 1)
Investigators
Xiangcai Ruan, MD, PhD
Professor
Sixth Affiliated Hospital, Sun Yat-sen University